The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.
ONCOLOGY® Companion, Volume 38, Supplement 7
A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.
Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up
2
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
3
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
4
Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer
5
